- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
Patent holdings for IPC class C07D 211/22
Total number of patents in this class: 592
10-year publication summary
|
40
|
48
|
31
|
48
|
25
|
44
|
33
|
28
|
30
|
6
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 550 |
28 |
| Novartis AG | 11238 |
15 |
| The General Hospital Corporation | 4517 |
12 |
| Global Blood Therapeutics, Inc. | 180 |
12 |
| Takeda Pharmaceutical Company Limited | 2961 |
11 |
| The Broad Institute, Inc. | 1584 |
11 |
| Massachusetts Institute of Technology | 9795 |
9 |
| Boehringer Ingelheim International GmbH | 4629 |
8 |
| Eastman Chemical Company | 2239 |
8 |
| Bristol-myers Squibb Company | 5080 |
7 |
| AstraZeneca AB | 3042 |
7 |
| Atrogi AB | 41 |
6 |
| Galderma Research & Development | 440 |
6 |
| Incyte Holdings Corporation | 609 |
6 |
| Vitae Pharmaceuticals, Inc. | 98 |
6 |
| Xenon Pharmaceuticals Inc. | 190 |
6 |
| Beam Therapeutics Inc. | 176 |
6 |
| Merck Sharp & Dohme LLC | 3689 |
6 |
| Genentech, Inc. | 3742 |
5 |
| Ind-Swift Laboratories Limited | 57 |
5 |
| Other owners | 412 |